The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
LDN Social Media
Get connected with us on social networks
Brittany - US: Multiple Sclerosis (MS) (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Linda Elsegood: I would like to introduce Brittany from the United States who takes LDN for Vasculitis and Multiple Sclerosis. Thanks for joining me, Brittany.
Brittany: Thank you.
Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness
Fatigue: Biomedicine, Health & Behavior
09 June 2018
https://www.tandfonline.com/doi/full/10.1080/21641846.2018.1477034?scroll=top&needAccess=true
Background: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities.
Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.